|  |  |  |
| --- | --- | --- |
| **#** | Search | Results of 3 April 2024 |
| 1 | pregnancy/ | 705,334 |
| 2 | diabetes insipidus/ | 12,566 |
| 3 | gestational diabetes insipidus.ti,ab. | 50 |
| 4 | diabetes insipidus.ti,ab. | 11,742 |
| 5 | pregnancy.ti,ab. | 606,067 |
| 6 | 2 or 4 | 16,238 |
| 7 | 1 or 5 | 954,515 |
| 8 | 6 and 7 | 652 |
| 9 | 3 or 8 | 658 |
| 10 | limit 9 to yr="1980 -Current" | 613 |
| 11 | limit 10 to embase status | 419 |

**Gestational diabetes insipidus. A systematic review of case reports.**

**Supplementary Material**

Table Suppl 1. Embase search strategy

Table Suppl 2. List of authors, year of publication, country and number of cases described.

|  |  |  |  |
| --- | --- | --- | --- |
| Author, reference | Year of publication | Country  | Number of cases |
| Marques P., et al.[7] | 2015 | United Kingdom | 1 |
| Dashraath P., et al.[24]  | 2022 | Singapore | 1 |
| Giacobbe A., et al.[25] | 2015 | Italy | 1 |
| Mor A., et al.[26] | 2015 | USA | 1 |
| Chong PL., et al.[5] | 2019 | Brunei | 1 |
| Krysiak R., et al.[27] | 2010 | Poland | 1 |
| Hanson RS., et al.[28]  | 1997 | USA | 1 |
| Katz VL., et al.[29] | 1987 | United Kingdom | 1 |
| Kennedy S., et al.[30] | 1994 | Australia | 6 |
| Krege J., et al.[31] | 1989 | USA | 1 |
| Combs CA., et al.[32]  | 1990 | USA | 1 |
| Brewster UC., et al.[53] | 2005 | USA | 1 |
| Kalelioglu I., et al.[33]  | 2007 | Turkey | 1 |
| El-Hennawy AS., et al.[34]  | 2003 | USA | 2 |
| Hughes JM., et al.[35] | 1989 | USA | 2 |
| Benchetrit S., et al.[36] | 2007 | Israel | 1 |
| Gambito R., et al.[37] | 2012 | USA | 1 |
| Siristatidis C., et al.[38]  | 2004 | Greece | 1 |
| Ford SM Jr., et al.[39] | 1986 | USA | 1 |
| Frenzer A., et al.[40]  | 1994 | Germany | 1 |
| Sainz Bueno JA., et al.[41] | 2005 | Spain | 1 |
| Kondo T., et al.[13] | 2018 | Japan | 1 |
| Wallia A., et al[42] | 2013 | USA | 1 |
| Álvarez Bernabéu R., et al.[43]  | 2014 | Spain | 1 |
| Vilouta M., et al.[44] | 2002 | Spain | 1 |
| Berteau P., et al.[45] | 1990 | France | 1 |
| De Mesmay M., et al.[46]  | 2013 | France | 1 |
| Mizuno O., et al.[47] | 1997 | Japan | 1 |
| Passannante AN., et al.[48] | 1995 | USA | 1 |
| Yamanaka Y., et al.[49] | 2002 | Japan | 1 |
| Raziel A., et al.[50] | 1991 | Israel | 2 |
| Ellidokuz E., et al.[51] | 2006 | Turkey | 1 |
| English N., et al.[52]  | 2015 | Australia | 1 |
| Woelk JL., et al.[15]  | 2010 | USA | 1 |
| Brewster UC., et al.[53]  | 2005 | USA | 2 |
| Weinberg LE., et al.[54]  | 2010 | USA | 1 |
| Jin-no Y., et al.[55] | 1998 | Japan | 1 |
| Aragón-Charris J., et al.[56] | 2004 | Spain | 1 |
| Barbey F., et al.[57] | 2003 | Switzerland | 1 |
| Price JT., et al.[58] | 2013 | USA  | 1 |
| van der Weiden RM., et al.[59] | 1987 | Netherlands | 1 |
| Sherer DM., et al.[60] | 2003 | USA | 1 |
| Wiser A., et al.[61]  | 2008 | Israel | 1 |
| Lacassie HJ., et al.[62] | 2005 | USA | 1 |
| Del Carpio-Orantes L.[63] | 2017 | Mexico | 1 |
| Sum M., et al.[64] | 2017 | USA | 1 |
| Goldrich A., et al.[14] | 2023 | USA | 1 |
| Rodrigo N., et al.[65] | 2018 | Australia | 1 |
| Abramova N., et al.[66] | 2021 | Ukraine | 1 |
| Nakamura M., et al.[67]  | 2016 | Japan | 1 |
| Wang HJ., et al.[16] | 2020 | Taiwan | 1 |
| Maharajh A., et al.[68] | 2021 | United Kingdom | 1 |
| Elkhomri A., et al.[69] | 2022 | Morocco | 1 |
| Razavi A., et al.[70] | 2017 | USA | 1 |
| Alkaabi JM., et al.[71]  | 2008 | United Arab Emirates | 1 |
| Total publications: 55 |  |  | Total clinical cases: 64 |

Table Suppl 3. JBI Critical Appraisal Checklist for Case Reports

|  |  |
| --- | --- |
| Question |  |
| Q1 | Were patient’s demographic characteristics clearly described? |
| Q2 | Was the patient’s history clearly described and presented as a timeline? |
| Q3 | Was the current clinical condition of the patient on presentation clearly described? |
| Q4 | Were diagnostic tests or assessment methods and the results clearly described?*A reader of the case report should be provided sufficient information to understand how the patient was assessed. It is important that all appropriate tests are ordered to confirm a diagnosis and therefore the case report should provide a clear description of various diagnostic tests used (whether a gold standard or alternative diagnostic tests).* |
| Q5 | Was the intervention(s) or treatment procedure(s) clearly described? |
| Q6 | Was the post-intervention clinical condition clearly described? |
| Q7 | Were adverse events (harms) or unanticipated events identified and described? |
| Q8 | Does the case report provide takeaway lessons? |

Table Suppl 4. JBI´s tool for assessing case series

|  |  |
| --- | --- |
| Question |  |
| Q1 | Were there clear criteria for inclusion in the case series? |
| Q2 | Was the condition measured in a standard, reliable way for all participants included in the case series? |
| Q3 | Were valid methods used for identification of the condition for all participants included in the case series? |
| Q4 | Did the case series have consecutive inclusion of participants? |
| Q5 | Did the case series have complete inclusion of participants? |
| Q6 | Was there clear reporting of the demographics of the participants included in the study? |
| Q7 | Was there clear reporting of clinical information of the participants? |
| Q8 | Were the outcomes or follow-up results of cases clearly reported? |
| Q9 | Was there clear reporting of the presenting sites’/clinics’ demographic information? |
| Q10 | Was statistical analysis appropriate? |